Φορτώνει......
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a few. The need for biomarkers for identification of a suitable patient populati...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Biomark Res |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5353958/ https://ncbi.nlm.nih.gov/pubmed/28331612 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-017-0093-8 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|